ALEMTUZUMAB Side Effects

7020231-4 | Nasopharyngitis, Pulmonary Tuberculosis, Sinus Tachycardia, Weight Decreased
on Sep 22, 2010 Female patient from UNITED STATES , 40 years of age, weighting 110.2 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), cough and was treated with Alemtuzumab (View Usage). Patient experienced the following unwanted or unexpected effects: nasopharyngitis, pulmonary tuberculosis, sinus tachycardia, weight decreased. Alemtuzumab dosage: . During the same period patient was treated with METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), ACYCLOVIR SODIUM (View Acyclovir Sodium Review and Acyclovir Sodium Label ), AUGMENTIN '125' (View Augmentin '125' Review and Augmentin '125' Label ). Patient was hospitalized.

7018717-1 | Blood Creatinine Increased, Dehydration, Gastroenteritis
Patient was taking Alemtuzumab (View Usage). Patient had the following side effects: blood creatinine increased, dehydration, gastroenteritis (What is gastroenteritis?) on Mar 29, 2010 from UNITED STATES Additional patient health information: Female patient , 40 years of age, weighting 194.0 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Alemtuzumab dosage: . During the same period patient was treated with METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ). Patient was hospitalized.

7018713-4 | Alanine Aminotransferase Increased, Chest Discomfort, Nausea, Oxygen Saturation Decreased, Refusal Of Treatment By Patient, Respiratory Rate Increased, Tachycardia, Urinary Tract Infection, Urine Output Decreased
Adverse event was reported on Sep 10, 2010 by a Female patient taking Alemtuzumab (View Usage) (Dosage: Month 0) was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Location: UNITED STATES , 31 years of age, After Alemtuzumab was administered, patient had the following side effects: alanine aminotransferase increased, chest discomfort, nausea (What is nausea?), oxygen saturation decreased, refusal of treatment by patient, respiratory rate increased, tachycardia, urinary tract infection (What is urinary tract infection?), urine output decreased. During the same period patient was treated with METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), SERTRALINE HYDROCHLORIDE (View Sertraline Hydrochloride Review and Sertraline Hydrochloride Label ), IOPERAMIDE (View Ioperamide Review and Ioperamide Label ), LACTULOSE (View Lactulose Review and Lactulose Label ), PICOLAX (View Picolax Review and Picolax Label ), CYCLIZINE (View Cyclizine Review and Cyclizine Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ). Patient was hospitalized.

7018711-0 | Labyrinthitis
on Sep 10, 2010 Female patient from UNITED STATES , 37 years of age, weighting 143.3 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Alemtuzumab (View Usage). Patient experienced the following unwanted or unexpected effects: labyrinthitis. Alemtuzumab dosage: . During the same period patient was treated with METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), LOVAN (View Lovan Review and Lovan Label ), KEFLEX (View Keflex Review and Keflex Label ), VALIUM (View Valium Review and Valium Label ), PANADOL (View Panadol Review and Panadol Label ), VENTOLIN (View Ventolin Review and Ventolin Label ), NASONEX (View Nasonex Review and Nasonex Label ). Patient was hospitalized.


7007224-8 | Nausea, Urinary Tract Infection, Urine Output Decreased
on Sep 10, 2010 Female patient from UNITED STATES , 31 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Alemtuzumab (View Usage). Patient had the following side effects: nausea (What is nausea?), urinary tract infection (What is urinary tract infection?), urine output decreased. Alemtuzumab dosage: Month 0. During the same period patient was treated with METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), SERTRALINE HYDROCHLORIDE (View Sertraline Hydrochloride Review and Sertraline Hydrochloride Label ), IOPERAMIDE (View Ioperamide Review and Ioperamide Label ), LACTULOSE (View Lactulose Review and Lactulose Label ), PICOLAX (View Picolax Review and Picolax Label ), CYCLIZINE (View Cyclizine Review and Cyclizine Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ). Patient was hospitalized.

7007221-2 | Asthenia, Diarrhoea, Dizziness, Gastroenteritis, Haematocrit Decreased, Haemoglobin Decreased, Labyrinthitis, Nausea, Sensory Disturbance
Patient was taking Alemtuzumab (View Usage). After Alemtuzumab was administered, patient had the following side effects: asthenia, diarrhoea, dizziness (What is dizziness?), gastroenteritis (What is gastroenteritis?), haematocrit decreased, haemoglobin decreased, labyrinthitis, nausea (What is nausea?), sensory disturbance on Sep 10, 2010 from UNITED STATES Additional patient health information: Female patient , 37 years of age, weighting 143.3 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Alemtuzumab dosage: . During the same period patient was treated with METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), LOVAN (View Lovan Review and Lovan Label ), KEFLEX (View Keflex Review and Keflex Label ), VALIUM (View Valium Review and Valium Label ), PANADOL (View Panadol Review and Panadol Label ), VENTOLIN (View Ventolin Review and Ventolin Label ), NASONEX (View Nasonex Review and Nasonex Label ). Patient was hospitalized.

7007197-8 | Blood Creatinine Increased, Dehydration, Gastroenteritis
Adverse event was reported on Mar 29, 2010 by a Female patient taking Alemtuzumab (View Usage) (Dosage: ) was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Location: UNITED STATES , 40 years of age, weighting 194.0 lb, Patient experienced the following unwanted or unexpected effects: blood creatinine increased, dehydration, gastroenteritis (What is gastroenteritis?). During the same period patient was treated with METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ). Patient was hospitalized.

7006020-5 | Blood Creatinine Increased, Dehydration, Gastroenteritis
on Mar 29, 2010 Female patient from FRANCE , weighting 194.0 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Alemtuzumab (View Usage). Patient had the following side effects: blood creatinine increased, dehydration, gastroenteritis (What is gastroenteritis?). Alemtuzumab dosage: 12 Mg, Qdx5. During the same period patient was treated with METHYLPREDNISOLONE (1.0 G, Qdx3) (View Methylprednisolone Review and Methylprednisolone Label ). Patient was hospitalized.

6998319-3 | Aspergillosis, Bone Marrow Failure, Chronic Lymphocytic Leukaemia Transformation, Epstein-barr Virus Associated Lymphoproliferative Disorder, Epstein-barr Virus Infection, Histiocytosis Haematophagic, Influenza, Mucormycosis, Multi-organ Failure
on Aug 09, 2010 Male patient from FRANCE , 59 years of age, was diagnosed with chronic lymphocytic leukaemia and was treated with Alemtuzumab (View Usage). After Alemtuzumab was administered, patient had the following side effects: aspergillosis, bone marrow failure, chronic lymphocytic leukaemia transformation, epstein-barr virus associated lymphoproliferative disorder, epstein-barr virus infection, histiocytosis haematophagic, influenza, mucormycosis, multi-organ failure. Alemtuzumab dosage: . During the same period patient was treated with FLUDARABINE (View Fludarabine Review and Fludarabine Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ).

6985286-1 | Labyrinthitis
Patient was taking Alemtuzumab (View Usage). Patient experienced the following unwanted or unexpected effects: labyrinthitis on Sep 10, 2010 from AUSTRALIA Additional patient health information: Female patient , weighting 143.3 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), anxiety (What is anxiety?), depression (What is depression?), prophylaxis urinary tract infection, insomnia and. Alemtuzumab dosage: 12 Mg, Qdx5. During the same period patient was treated with METHYLPREDNISOLONE (1 G, Qdx3) (View Methylprednisolone Review and Methylprednisolone Label ), LOVAN (20 Mg, Qd) (View Lovan Review and Lovan Label ), KEFLEX (250 Mg, Prn) (View Keflex Review and Keflex Label ), VALIUM (1 Mg, Prn) (View Valium Review and Valium Label ), PANADOL (500 Mg, Prn) (View Panadol Review and Panadol Label ), VENTOLIN (100 Mcg, Prn) (View Ventolin Review and Ventolin Label ), NASONEX (1 Spray, Bid) (View Nasonex Review and Nasonex Label ). Patient was hospitalized.

6985285-X | Aspergillosis, Bone Marrow Failure, Chronic Lymphocytic Leukaemia Transformation, Epstein-barr Virus Associated Lymphoproliferative Disorder, Epstein-barr Virus Infection, Histiocytosis Haematophagic, Influenza, Mucormycosis, Multi-organ Failure
Adverse event was reported on Aug 09, 2010 by a Male patient taking Alemtuzumab (View Usage) (Dosage: ) was diagnosed with chronic lymphocytic leukaemia and. Location: FRANCE , 59 years of age, Patient had the following side effects: aspergillosis, bone marrow failure, chronic lymphocytic leukaemia transformation, epstein-barr virus associated lymphoproliferative disorder, epstein-barr virus infection, histiocytosis haematophagic, influenza, mucormycosis, multi-organ failure. During the same period patient was treated with FLUDARABINE (View Fludarabine Review and Fludarabine Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ).

6985279-4 | Dysfunctional Uterine Bleeding, Headache, Suicidal Ideation
on Sep 07, 2010 Female patient from UNITED STATES , 40 years of age, weighting 191.8 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), hypothyroidism, hypertension, pulmonary embolism (What is pulmonary embolism?) and was treated with Alemtuzumab (View Usage). After Alemtuzumab was administered, patient had the following side effects: dysfunctional uterine bleeding, headache (What is headache?), suicidal ideation. Alemtuzumab dosage: Total Daily Dose: 24 Mg. During the same period patient was treated with VICODIN (View Vicodin Review and Vicodin Label ), FENTANYL CITRATE (View Fentanyl Citrate Review and Fentanyl Citrate Label ), SYNTHROID (Total Daily Dose: 0.05 Mg) (View Synthroid Review and Synthroid Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ), WARFARIN SODIUM (View Warfarin Sodium Review and Warfarin Sodium Label ). Patient was hospitalized.

6981288-X | Aspergillosis, Bone Marrow Failure, Chronic Lymphocytic Leukaemia Transformation, Epstein-barr Virus Associated Lymphoproliferative Disorder, Epstein-barr Virus Infection, Histiocytosis Haematophagic, Influenza, Mucormycosis, Multi-organ Failure
on Aug 09, 2010 Male patient from FRANCE , 59 years of age, was diagnosed with chronic lymphocytic leukaemia and was treated with Alemtuzumab (View Usage). Patient experienced the following unwanted or unexpected effects: aspergillosis, bone marrow failure, chronic lymphocytic leukaemia transformation, epstein-barr virus associated lymphoproliferative disorder, epstein-barr virus infection, histiocytosis haematophagic, influenza, mucormycosis, multi-organ failure. Alemtuzumab dosage: . During the same period patient was treated with FLUDARABINE (View Fludarabine Review and Fludarabine Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ).

6980276-7 | Dysfunctional Uterine Bleeding, Headache, Suicidal Ideation
Patient was taking Alemtuzumab (View Usage). Patient had the following side effects: dysfunctional uterine bleeding, headache (What is headache?), suicidal ideation on Sep 07, 2010 from UNITED STATES Additional patient health information: Female patient , 40 years of age, weighting 191.8 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), hypothyroidism, hypertension, pulmonary embolism (What is pulmonary embolism?) and. Alemtuzumab dosage: Total Daily Dose: 24 Mg. During the same period patient was treated with VICODIN (View Vicodin Review and Vicodin Label ), FENTANYL CITRATE (View Fentanyl Citrate Review and Fentanyl Citrate Label ), SYNTHROID (Total Daily Dose: 0.05 Mg) (View Synthroid Review and Synthroid Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ), WARFARIN SODIUM (View Warfarin Sodium Review and Warfarin Sodium Label ). Patient was hospitalized.

6970219-4 | Retinal Pigment Epitheliopathy
Adverse event was reported on Aug 26, 2010 by a Male patient taking Alemtuzumab (View Usage) (Dosage: Month 0) was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Location: UNITED STATES , 35 years of age, After Alemtuzumab was administered, patient had the following side effects: retinal pigment epitheliopathy. During the same period patient was treated with METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), AMOXICILLIN (View Amoxicillin Review and Amoxicillin Label ). Patient was hospitalized.

6962365-6 | Autoimmune Thrombocytopenia, Megakaryocytes Increased, Neutrophil Count Decreased
on Aug 19, 2010 Female patient from UNITED STATES , 63 years of age, was diagnosed with lymphocytic leukaemia, antifungal prophylaxis and was treated with Alemtuzumab (View Usage). Patient experienced the following unwanted or unexpected effects: autoimmune thrombocytopenia, megakaryocytes increased, neutrophil count decreased. Alemtuzumab dosage: Day 1. During the same period patient was treated with TRIMETHOPRIM + SULFAMETHOXAZOLE (View Trimethoprim + Sulfamethoxazole Review and Trimethoprim + Sulfamethoxazole Label ).

6938424-0 | Bronchopneumonia, Candida Pneumonia, Febrile Neutropenia, Pseudomonal Sepsis, Respiratory Failure, Septic Shock, Tracheitis
on Jul 22, 2010 Male patient from GERMANY , 61 years of age, was diagnosed with t-cell lymphoma and was treated with Alemtuzumab (View Usage). Patient had the following side effects: bronchopneumonia, candida pneumonia, febrile neutropenia, pseudomonal sepsis, respiratory failure, septic shock, tracheitis. Alemtuzumab dosage: A-chop-14, Treatment Days 1 And 2 In Cycles 2 To 6. During the same period patient was treated with PREDNISONE (A-chop-14, Treatment Days 1-5 Per Cycle) (View Prednisone Review and Prednisone Label ), CYCLOPHOSPHAMIDE (A-chop-14, Treatment Day 1 Per Cycle) (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (A-chop-14, Treatment Day 1 Per Cycle) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (A-chop-14, Treatment Day 1 Per Cycle) (View Vincristine Review and Vincristine Label ). Patient was hospitalized.

6938178-8 | Pulmonary Tuberculosis
Patient was taking Alemtuzumab (View Usage). After Alemtuzumab was administered, patient had the following side effects: pulmonary tuberculosis on Aug 12, 2010 from UNITED STATES Additional patient health information: Female patient , 40 years of age, weighting 110.2 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), cough and. Alemtuzumab dosage: . During the same period patient was treated with METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), AUGMENTIN '125' (View Augmentin '125' Review and Augmentin '125' Label ). Patient was hospitalized.

6933245-7 | Haemoptysis
Adverse event was reported on Aug 09, 2010 by a Male patient taking Alemtuzumab (View Usage) (Dosage: Month 0) was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Location: UNITED STATES , 33 years of age, weighting 189.6 lb, Patient experienced the following unwanted or unexpected effects: haemoptysis. During the same period patient was treated with METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), POTASSIUM CHLORIDE (View Potassium Chloride Review and Potassium Chloride Label ). Patient was hospitalized.

6929529-9 | Acanthamoeba Infection, Pseudomonal Sepsis
on Jul 28, 2010 Male patient from UNITED STATES , 63 years of age, was diagnosed with acute graft versus host disease and was treated with Alemtuzumab (View Usage). Patient had the following side effects: acanthamoeba infection, pseudomonal sepsis. Alemtuzumab dosage: Escalated To 30 Mg/day 3 Times A Week For 6 Weeks, Then 10 Mg/day 3 Times A Week. During the same period patient was treated with RITUXIMAB (1 Course) (View Rituximab Review and Rituximab Label ), DACLIZUMAB (1 Course; Day 1, Day 4, Day 8, Day 15, Day 22) (View Daclizumab Review and Daclizumab Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), MYCOPHENOLATE MOFETIL (Unit Dose: 1000 Mg) (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ).

6927726-X | Agitation, Disseminated Intravascular Coagulation, Haemoglobin Decreased, Hypotension, Lactic Acidosis, Metabolic Acidosis, Post Procedural Haemorrhage, Shock Haemorrhagic
on Aug 04, 2010 Male patient from UNITED STATES , 51 years of age, was diagnosed with renal transplant and was treated with Alemtuzumab (View Usage). After Alemtuzumab was administered, patient had the following side effects: agitation, disseminated intravascular coagulation, haemoglobin decreased, hypotension, lactic acidosis, metabolic acidosis, post procedural haemorrhage, shock haemorrhagic. Alemtuzumab dosage: . During the same period patient was treated with SOLU MEDROL (View Solu-medrol Review and Solu-medrol Label ).

6920631-4 | Acanthamoeba Infection, Pseudomonal Sepsis
Patient was taking Alemtuzumab (View Usage). Patient experienced the following unwanted or unexpected effects: acanthamoeba infection, pseudomonal sepsis on Jul 28, 2010 from UNITED STATES Additional patient health information: Male patient , 63 years of age, was diagnosed with acute graft versus host disease and. Alemtuzumab dosage: Escalated To 30 Mg/day 3 Times A Week For 6 Weeks, Then 10 Mg/day 3 Times A Week. During the same period patient was treated with RITUXIMAB (1 Course) (View Rituximab Review and Rituximab Label ), ZENAPAX (1 Course; Day 1, Day 4, Day 8, Day 15, Day 22) (View Zenapax Review and Zenapax Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), MYCOPHENOLATE MOFETIL (Unit Dose: 1000 Mg) (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ).

6918581-2 | Agitation, Disseminated Intravascular Coagulation, Haemoglobin Decreased, Hypotension, Lactic Acidosis, Metabolic Acidosis, Post Procedural Haemorrhage, Shock Haemorrhagic
Adverse event was reported on Aug 04, 2010 by a Male patient taking Alemtuzumab (View Usage) (Dosage: ) was diagnosed with renal transplant and. Location: UNITED STATES , 51 years of age, Patient had the following side effects: agitation, disseminated intravascular coagulation, haemoglobin decreased, hypotension, lactic acidosis, metabolic acidosis, post procedural haemorrhage, shock haemorrhagic. During the same period patient was treated with SOLU MEDROL (View Solu-medrol Review and Solu-medrol Label ).

6913517-2 | Oxygen Saturation Decreased, Pyrexia, Respiratory Rate Increased, Tachycardia, Urine Output Decreased, Vomiting
on Jul 13, 2010 Female patient from UNITED STATES , 31 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Alemtuzumab (View Usage). After Alemtuzumab was administered, patient had the following side effects: oxygen saturation decreased, pyrexia, respiratory rate increased, tachycardia, urine output decreased, vomiting. Alemtuzumab dosage: Month 0. During the same period patient was treated with SERTRALINE HYDROCHLORIDE (View Sertraline Hydrochloride Review and Sertraline Hydrochloride Label ), IOPERAMIDE (View Ioperamide Review and Ioperamide Label ), LACTULOSE (View Lactulose Review and Lactulose Label ), PICOLAX (View Picolax Review and Picolax Label ), CYCLIZINE (View Cyclizine Review and Cyclizine Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), SEVERADOL (View Severadol Review and Severadol Label ). Patient was hospitalized.

6909010-3 | Oxygen Saturation Decreased, Pyrexia, Respiratory Rate Increased, Tachycardia, Urine Output Decreased, Vomiting
on Jul 13, 2010 Female patient from UNITED STATES , 31 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Alemtuzumab (View Usage). Patient experienced the following unwanted or unexpected effects: oxygen saturation decreased, pyrexia, respiratory rate increased, tachycardia, urine output decreased, vomiting. Alemtuzumab dosage: Month 0. During the same period patient was treated with SERTRALINE HYDROCHLORIDE (View Sertraline Hydrochloride Review and Sertraline Hydrochloride Label ), IOPERAMIDE (View Ioperamide Review and Ioperamide Label ), LACTULOSE (View Lactulose Review and Lactulose Label ), PICOLAX (View Picolax Review and Picolax Label ), CYCLIZINE (View Cyclizine Review and Cyclizine Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), SEVERADOL (View Severadol Review and Severadol Label ). Patient was hospitalized.

6883815-X | Acute Respiratory Failure, Anaemia, Dyspnoea, Haemoptysis, Large Intestine Perforation, Pulmonary Alveolar Haemorrhage, Renal Failure Acute, Renal Tubular Necrosis, Thrombocytopenia
Patient was taking Alemtuzumab (View Usage). Patient had the following side effects: acute respiratory failure, anaemia, dyspnoea, haemoptysis, large intestine perforation, pulmonary alveolar haemorrhage, renal failure acute, renal tubular necrosis, thrombocytopenia on Jul 14, 2010 from UNITED STATES Additional patient health information: Male patient , 26 years of age, was diagnosed with immunosuppression, alport's syndrome and. Alemtuzumab dosage: Total Daily Dose: 30 Mg. During the same period patient was treated with LISINOPRIL (View Lisinopril Review and Lisinopril Label ), MULTI VITAMINS (View Multi-vitamins Review and Multi-vitamins Label ), CALCIUM ACETATE (View Calcium Acetate Review and Calcium Acetate Label ), TACROLIMUS (Starting 4 Days After Transplantation Surgery) (View Tacrolimus Review and Tacrolimus Label ). Patient was hospitalized.

6882479-9 | Multiple Sclerosis Relapse
Adverse event was reported on Jul 16, 2010 by a Male patient taking Alemtuzumab (View Usage) (Dosage: ) was diagnosed with multiple sclerosis relapse and. Location: UNITED STATES , 52 years of age, After Alemtuzumab was administered, patient had the following side effects: multiple sclerosis relapse. Patient was hospitalized.

6882409-X | Bronchopneumonia, Candida Pneumonia, Febrile Neutropenia, Pseudomonal Sepsis, Respiratory Failure, Septic Shock, Tracheitis
on Jul 22, 2010 Male patient from GERMANY , 61 years of age, was diagnosed with t-cell lymphoma and was treated with Alemtuzumab (View Usage). Patient experienced the following unwanted or unexpected effects: bronchopneumonia, candida pneumonia, febrile neutropenia, pseudomonal sepsis, respiratory failure, septic shock, tracheitis. Alemtuzumab dosage: A-chop-14, Treatment Days 1 And 2 In Cycles 2 To 6. During the same period patient was treated with PREDNISONE (A-chop-14, Treatment Days 1-5 Per Cycle) (View Prednisone Review and Prednisone Label ), CYCLOPHOSPHAMIDE (A-chop-14, Treatment Day 1 Per Cycle) (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (A-chop-14, Treatment Day 1 Per Cycle) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (A-chop-14, Treatment Day 1 Per Cycle) (View Vincristine Review and Vincristine Label ). Patient was hospitalized.

6879013-6 | C-reactive Protein Increased, Chronic Lymphocytic Leukaemia, Chronic Obstructive Pulmonary Disease, Dyspnoea, Leukopenia, Neutropenia, Pain, Pneumonia
on Jul 16, 2010 Male patient from GERMANY , 63 years of age, weighting 149.9 lb, was diagnosed with chronic lymphocytic leukaemia recurrent and was treated with Alemtuzumab (View Usage). Patient had the following side effects: c-reactive protein increased, chronic lymphocytic leukaemia, chronic obstructive pulmonary disease, dyspnoea, leukopenia, neutropenia, pain (What is pain?), pneumonia (What is pneumonia?). Alemtuzumab dosage: Dose Escalation And Cycle 1. During the same period patient was treated with FLUDARABINE PHOSPHATE (Cycle 1) (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), CYCLOPHOSPHAMIDE (Cycle 1) (View Cyclophosphamide Review and Cyclophosphamide Label ), TAMSULOSIN HCL (View Tamsulosin Hcl Review and Tamsulosin Hcl Label ), TRIMIPRAMINMALEAT (View Trimipraminmaleat Review and Trimipraminmaleat Label ), TIOTROPIUMBROMID (View Tiotropiumbromid Review and Tiotropiumbromid Label ), FORMOTEROLHEMIFUMARAT (View Formoterolhemifumarat Review and Formoterolhemifumarat Label ), CIPROFLOXACIN (View Ciprofloxacin Review and Ciprofloxacin Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ). Patient was hospitalized.

6879001-X | Circulatory Collapse, Coagulopathy, Convulsion, Disseminated Cytomegaloviral Infection, Encephalitis, Hepatic Failure, Hepatitis, Herpes Simplex, Influenza Like Illness
Patient was taking Alemtuzumab (View Usage). After Alemtuzumab was administered, patient had the following side effects: circulatory collapse, coagulopathy, convulsion, disseminated cytomegaloviral infection, encephalitis (What is encephalitis?), hepatic failure, hepatitis (What is hepatitis?), herpes simplex (What is herpes simplex?), influenza like illness on Jul 16, 2010 from UNITED STATES Additional patient health information: Male patient , 41 years of age, was diagnosed with chronic lymphocytic leukaemia recurrent and. Alemtuzumab dosage: Dose Escalation Day 1:3 Mg - Day 2: 10mg - Day 3: 30 Mg. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

6878935-X | C-reactive Protein Increased, Chronic Lymphocytic Leukaemia, Chronic Obstructive Pulmonary Disease, Dyspnoea, Leukopenia, Neutropenia, Pain, Pneumonia
Adverse event was reported on Jul 16, 2010 by a Male patient taking Alemtuzumab (View Usage) (Dosage: Dose Escalation And Cycle 1) was diagnosed with chronic lymphocytic leukaemia recurrent and. Location: GERMANY , 63 years of age, weighting 149.9 lb, Patient experienced the following unwanted or unexpected effects: c-reactive protein increased, chronic lymphocytic leukaemia, chronic obstructive pulmonary disease, dyspnoea, leukopenia, neutropenia, pain (What is pain?), pneumonia (What is pneumonia?). During the same period patient was treated with FLUDARABINE PHOSPHATE (Cycle 1) (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), CYCLOPHOSPHAMIDE (Cycle 1) (View Cyclophosphamide Review and Cyclophosphamide Label ), TAMSULOSIN HCL (View Tamsulosin Hcl Review and Tamsulosin Hcl Label ), TRIMIPRAMINMALEAT (View Trimipraminmaleat Review and Trimipraminmaleat Label ), TIOTROPIUMBROMID (View Tiotropiumbromid Review and Tiotropiumbromid Label ), FORMOTEROLHEMIFUMARAT (View Formoterolhemifumarat Review and Formoterolhemifumarat Label ), CIPROFLOXACIN (View Ciprofloxacin Review and Ciprofloxacin Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ). Patient was hospitalized.

6878930-0 | Circulatory Collapse, Coagulopathy, Convulsion, Disseminated Cytomegaloviral Infection, Encephalitis, Hepatic Failure, Hepatitis, Herpes Simplex, Influenza Like Illness
on Jul 16, 2010 Male patient from UNITED STATES , 41 years of age, was diagnosed with chronic lymphocytic leukaemia recurrent and was treated with Alemtuzumab (View Usage). Patient had the following side effects: circulatory collapse, coagulopathy, convulsion, disseminated cytomegaloviral infection, encephalitis (What is encephalitis?), hepatic failure, hepatitis (What is hepatitis?), herpes simplex (What is herpes simplex?), influenza like illness. Alemtuzumab dosage: Dose Escalation Day 1:3 Mg - Day 2: 10mg - Day 3: 30 Mg. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

6878928-2 | Pulmonary Tuberculosis
on Jul 14, 2010 Female patient from UNITED STATES , 40 years of age, weighting 110.2 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), cough and was treated with Alemtuzumab (View Usage). After Alemtuzumab was administered, patient had the following side effects: pulmonary tuberculosis. Alemtuzumab dosage: . During the same period patient was treated with METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), AUGMENTIN '125' (View Augmentin '125' Review and Augmentin '125' Label ). Patient was hospitalized.

6878893-8 | Menorrhagia
Patient was taking Alemtuzumab (View Usage). Patient experienced the following unwanted or unexpected effects: menorrhagia on Jul 12, 2010 from UNITED STATES Additional patient health information: Female patient , 39 years of age, weighting 235.9 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Alemtuzumab dosage: . During the same period patient was treated with METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), GABAPENTIN (View Gabapentin Review and Gabapentin Label ), FLUOXETINE (View Fluoxetine Review and Fluoxetine Label ). Patient was hospitalized.

6862283-8 | Oxygen Saturation Decreased, Pyrexia, Respiratory Rate Increased, Tachycardia, Urine Output Decreased, Vomiting
Adverse event was reported on Jul 05, 2010 by a Female patient taking Alemtuzumab (View Usage) (Dosage: Month 0) was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Location: UNITED STATES , 31 years of age, Patient had the following side effects: oxygen saturation decreased, pyrexia, respiratory rate increased, tachycardia, urine output decreased, vomiting. During the same period patient was treated with TRIMETHOPRIN (View Trimethoprin Review and Trimethoprin Label ), SERTRALINE HCL (View Sertraline Hcl Review and Sertraline Hcl Label ), IOPERAMIDE (View Ioperamide Review and Ioperamide Label ), LACTULOSE (View Lactulose Review and Lactulose Label ), PICOLAX (View Picolax Review and Picolax Label ), CYCLIZINE (View Cyclizine Review and Cyclizine Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ). Patient was hospitalized.

6856692-0 | Cytomegalovirus Infection, Pancytopenia, Pneumonia Legionella, Pyrexia
on Jul 10, 2010 Female patient from UNITED STATES , 62 years of age, was diagnosed with angioimmunoblastic t-cell lymphoma refractory, antiviral prophylaxis and was treated with Alemtuzumab (View Usage). After Alemtuzumab was administered, patient had the following side effects: cytomegalovirus infection (What is cytomegalovirus infection?), pancytopenia, pneumonia legionella, pyrexia. Alemtuzumab dosage: . During the same period patient was treated with FAMCICLOVIR (View Famciclovir Review and Famciclovir Label ).

6856691-9 | Angioimmunoblastic T-cell Lymphoma Recurrent, Cytomegalovirus Infection, Febrile Neutropenia, Thrombocytopenia
on Jul 10, 2010 Female patient from UNITED STATES , 73 years of age, was diagnosed with angioimmunoblastic t-cell lymphoma recurrent, antibiotic prophylaxis, antiviral prophylaxis and was treated with Alemtuzumab (View Usage). Patient experienced the following unwanted or unexpected effects: angioimmunoblastic t-cell lymphoma recurrent, cytomegalovirus infection (What is cytomegalovirus infection?), febrile neutropenia, thrombocytopenia. Alemtuzumab dosage: . During the same period patient was treated with PREDNISONE (View Prednisone Review and Prednisone Label ), BACTRIM (View Bactrim Review and Bactrim Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ).

6856690-7 | Agranulocytosis, Anaemia Haemolytic Autoimmune, Bronchopulmonary Aspergillosis, Pancytopenia
Patient was taking Alemtuzumab (View Usage). Patient had the following side effects: agranulocytosis, anaemia haemolytic autoimmune, bronchopulmonary aspergillosis, pancytopenia on Jul 10, 2010 from UNITED STATES Additional patient health information: Male patient , 73 years of age, was diagnosed with angioimmunoblastic t-cell lymphoma recurrent, lymphadenopathy and. Alemtuzumab dosage: 6 Cycles. During the same period patient was treated with CYTOXAN (1 Cycle) (View Cytoxan Review and Cytoxan Label ).

6847374-X | Angioimmunoblastic T-cell Lymphoma Recurrent, Cytomegalovirus Infection, Febrile Neutropenia, Thrombocytopenia
Adverse event was reported on Jul 10, 2010 by a Female patient taking Alemtuzumab (View Usage) (Dosage: ) was diagnosed with angioimmunoblastic t-cell lymphoma recurrent, antibiotic prophylaxis, antiviral prophylaxis and. Location: UNITED STATES , 73 years of age, After Alemtuzumab was administered, patient had the following side effects: angioimmunoblastic t-cell lymphoma recurrent, cytomegalovirus infection (What is cytomegalovirus infection?), febrile neutropenia, thrombocytopenia. During the same period patient was treated with PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), BACTRIM (View Bactrim Review and Bactrim Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ).

6847373-8 | Retinal Pigment Epitheliopathy
on Jul 07, 2010 Male patient from UNITED STATES , 35 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Alemtuzumab (View Usage). Patient experienced the following unwanted or unexpected effects: retinal pigment epitheliopathy. Alemtuzumab dosage: Month 0. During the same period patient was treated with METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), AMOXICILLIN (View Amoxicillin Review and Amoxicillin Label ). Patient was hospitalized.

6840167-9 | Chest Discomfort, Nausea, Oxygen Saturation Decreased, Pyrexia, Respiratory Rate Increased, Tachycardia, Urinary Tract Infection, Urine Output Decreased
on Jul 05, 2010 Female patient from UNITED STATES , 31 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Alemtuzumab (View Usage). Patient had the following side effects: chest discomfort, nausea (What is nausea?), oxygen saturation decreased, pyrexia, respiratory rate increased, tachycardia, urinary tract infection (What is urinary tract infection?), urine output decreased. Alemtuzumab dosage: Month 0. During the same period patient was treated with TRIMETHOPRIN (View Trimethoprin Review and Trimethoprin Label ), SERTRALINE HCL (View Sertraline Hcl Review and Sertraline Hcl Label ), IOPERAMIDE (View Ioperamide Review and Ioperamide Label ), LACTULOSE (View Lactulose Review and Lactulose Label ), PICOLAX (View Picolax Review and Picolax Label ), CYCLIZINE (View Cyclizine Review and Cyclizine Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ). Patient was hospitalized.

6840143-6 | Menorrhagia
Patient was taking Alemtuzumab (View Usage). After Alemtuzumab was administered, patient had the following side effects: menorrhagia on Jul 02, 2010 from UNITED STATES Additional patient health information: Female patient , 39 years of age, weighting 235.9 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Alemtuzumab dosage: . During the same period patient was treated with METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), GABAPENTIN (View Gabapentin Review and Gabapentin Label ), FLUOXETINE HCL (View Fluoxetine Hcl Review and Fluoxetine Hcl Label ). Patient was hospitalized.

6835254-5 | Cachexia, Cytomegalovirus Viraemia, Dermatitis Exfoliative, Diarrhoea, Gastrointestinal Candidiasis, Renal Failure
Adverse event was reported on Jun 30, 2010 by a Male patient taking Alemtuzumab (View Usage) (Dosage: ) was diagnosed with t-cell lymphoma, gastrointestinal candidiasis, antiviral prophylaxis, supraventricular extrasystoles and. Location: GERMANY , 48 years of age, Patient experienced the following unwanted or unexpected effects: cachexia, cytomegalovirus viraemia, dermatitis exfoliative, diarrhoea, gastrointestinal candidiasis, renal failure. During the same period patient was treated with PREDNISONE (View Prednisone Review and Prednisone Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), NEUPOGEN (Not Applicable) (View Neupogen Review and Neupogen Label ), VORICONAZOLE (Total Daily Dose: 400 Mg) (View Voriconazole Review and Voriconazole Label ), ACYCLOVIR (Total Daily Dose: 1200 Mg) (View Acyclovir Review and Acyclovir Label ), PROPAFENONE HCL (Total Daily Dose: 450 Mg) (View Propafenone Hcl Review and Propafenone Hcl Label ).

6830901-6 | Cervical Dysplasia
on Jun 28, 2010 Female patient from UNITED STATES , 26 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Alemtuzumab (View Usage). Patient had the following side effects: cervical dysplasia. Alemtuzumab dosage: .

6826184-3 | Multiple Sclerosis Relapse
on Jun 25, 2010 Male patient from UNITED STATES , 52 years of age, was diagnosed with multiple sclerosis relapse and was treated with Alemtuzumab (View Usage). After Alemtuzumab was administered, patient had the following side effects: multiple sclerosis relapse. Alemtuzumab dosage: . Patient was hospitalized.

6826143-0 | Cachexia, Cytomegalovirus Viraemia, Dermatitis Exfoliative, Diarrhoea, Gastrointestinal Candidiasis, Renal Failure
Patient was taking Alemtuzumab (View Usage). Patient experienced the following unwanted or unexpected effects: cachexia, cytomegalovirus viraemia, dermatitis exfoliative, diarrhoea, gastrointestinal candidiasis, renal failure on Jun 30, 2010 from GERMANY Additional patient health information: Male patient , 48 years of age, was diagnosed with t-cell lymphoma, gastrointestinal candidiasis, antiviral prophylaxis, supraventricular extrasystoles and. Alemtuzumab dosage: . During the same period patient was treated with PREDNISONE (View Prednisone Review and Prednisone Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), NEUPOGEN (Not Applicable) (View Neupogen Review and Neupogen Label ), VORICONAZOLE (Total Daily Dose: 400 Mg) (View Voriconazole Review and Voriconazole Label ), ACYCLOVIR (Total Daily Dose: 1200 Mg) (View Acyclovir Review and Acyclovir Label ), PROPAFENONE HCL (Total Daily Dose: 450 Mg) (View Propafenone Hcl Review and Propafenone Hcl Label ).

6822062-4 | Tachycardia
Adverse event was reported on Jun 25, 2010 by a Female patient taking Alemtuzumab (View Usage) (Dosage: Total Daily Dose: 12 Mg) was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Location: UNITED STATES , 47 years of age, weighting 158.7 lb, Patient had the following side effects: tachycardia. During the same period patient was treated with LAXATIVES (View Laxatives Review and Laxatives Label ), ZYRTEC (View Zyrtec Review and Zyrtec Label ), IBUPROFEN (View Ibuprofen Review and Ibuprofen Label ).

6819298-5 | Cystitis Haemorrhagic
on Jun 26, 2010 Male patient from UNITED KINGDOM , 56 years of age, was diagnosed with stem cell transplant, t-cell prolymphocytic leukaemia and was treated with Alemtuzumab (View Usage). After Alemtuzumab was administered, patient had the following side effects: cystitis haemorrhagic. Alemtuzumab dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ).

6816612-1 | Headache, Hysterectomy, Suicidal Ideation
on Jun 30, 2010 Female patient from UNITED STATES , 40 years of age, weighting 191.8 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), hypothyroidism, hypertension, pulmonary embolism (What is pulmonary embolism?) and was treated with Alemtuzumab (View Usage). Patient experienced the following unwanted or unexpected effects: headache (What is headache?), hysterectomy (What is hysterectomy?), suicidal ideation. Alemtuzumab dosage: Total Daily Dose: 24 Mg. During the same period patient was treated with VICODIN (View Vicodin Review and Vicodin Label ), FENTANYL (View Fentanyl Review and Fentanyl Label ), SYNTHROID (Total Daily Dose: 0.05 Mg) (View Synthroid Review and Synthroid Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ), WARFARIN (View Warfarin Review and Warfarin Label ). Patient was hospitalized.

6816270-6 | Multi-organ Failure, Pneumonitis
Patient was taking Alemtuzumab (View Usage). Patient had the following side effects: multi-organ failure, pneumonitis on Jun 26, 2010 from UNITED KINGDOM Additional patient health information: Male patient , 58 years of age, was diagnosed with stem cell transplant, t-cell prolymphocytic leukaemia and. Alemtuzumab dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ).